Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ: PHAT · IEX Real-Time Price · USD
14.96 -0.20 (-1.32%)
Jan 18, 2022 3:10 PM EST - Market open
Market Cap473.39M
Revenue (ttm)n/a
Net Income (ttm)-161.78M
Shares Out31.64M
EPS (ttm)-4.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume33,784
Open15.11
Previous Close15.16
Day's Range14.04 - 15.65
52-Week Range14.04 - 50.78
Beta1.07
AnalystsBuy
Price Target54.83 (+266.5%)
Earnings DateNov 9, 2021

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection...

IndustryPharmaceuticals
IPO DateOct 25, 2019
Employees55
Stock ExchangeNASDAQ
Ticker SymbolPHAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is 54.83, which is an increase of 266.51% from the latest price.

Price Target
$54.83
(266.51% upside)
Analyst Consensus: Buy

News

Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference

FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

1 month ago - GlobeNewsWire

Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences

FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals Withdraws Public Offering

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock

FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

2 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

2 months ago - GlobeNewsWire

Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has announced data from the PHALCON-EE Phase 3 trial evaluating vonoprazan versus lansoprazole for erosive esophagitis (EE).  Esophagitis is inflammation, irri...

3 months ago - Benzinga

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

FLORHAM PARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

3 months ago - GlobeNewsWire

Phathom Pharma's Vonoprazan Inhibits Gastric Acid In Healthy Volunteers

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has reported results from the VONO-103 Phase 1 trial of vonoprazan in healthy subjects. The trial evaluated the effects of vonoprazan 20 mg once daily and lans...

3 months ago - Benzinga

Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonopr...

Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID®) 30 mg, a proton pump inhibitor (PPI)

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

3 months ago - GlobeNewsWire

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. ...

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

4 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

4 months ago - GlobeNewsWire

Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory...

FLORHAM PARK, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.

FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI

FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

5 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

7 months ago - GlobeNewsWire

Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates

FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

8 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

8 months ago - GlobeNewsWire

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter p...

FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

8 months ago - GlobeNewsWire

Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

9 months ago - GlobeNewsWire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Busin...

FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

9 months ago - GlobeNewsWire

Why Mustang Bio, Phathom Pharma And More Are Moving Today

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first...

Other symbols:MBIOBNGOIMVT
11 months ago - Benzinga

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori)...

FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

11 months ago - GlobeNewsWire

Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and M...

Other symbols:PASG
1 year ago - Business Wire